Cibus (CBUS) EBIT Margin (2016 - 2026)

Cibus (CBUS) posted EBIT Margin of 2135.67% for Q4 2025, up 14.92% sequentially from 2510.24% in Q3 2025, and down 64854.0% YoY from N/an in Q4 2024.

Cibus (CBUS) EBIT Margin (2016 - 2026) Analysis & Trends

Cibus has reported EBIT Margin for 10 years, with the latest figure at 2135.67% in Q4 2025.

Quarterly EBIT Margin fell 64854.0% year-over-year to 2135.67% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2680.1% (up 338268.0% YoY) and the FY2025 annual result came in at 2680.1%, up 338268.0% from the prior year.
EBIT Margin grew to 2135.67% in Q4 2025 per CBUS's latest filing, from 2510.24% in the prior quarter.
Over five years, EBIT Margin peaked at 50.37% in Q2 2021 and troughed at 24416.32% in Q4 2023.
A 5-year average of 6960.83% and a median of 3703.14% in 2024 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2022 and 2024: EBIT Margin slumped 1880820 bps in 2022, then soared 2292919 bps in 2024.
Over 5 years, EBIT Margin stood at 345.34% in 2021, then slumped by 2184 bps to 7888.1% in 2022, then plunged by 210 bps to 24416.32% in 2023, then jumped by 94 bps to 1487.13% in 2024, then sank by 44 bps to 2135.67% in 2025.
According to Business Quant data, EBIT Margin over the past three periods registered 2135.67%, 2510.24%, and 1923.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	138.41 Bn	130.56 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.12 Bn	78.12 Bn	3.93 Bn	30.15%
3	Argenx Se	64.41 Bn	59.23 Bn	1.37 Bn	32.54%
4	Moderna	57.56 Bn	52.43 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.06 Bn	36.96 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.95 Bn	27.65 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.48 Bn	9.09 Bn	668.28 Mn	-35.57%
8	Insmed	27.31 Bn	26.15 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.04 Bn	26.20 Bn	-	19.75%
10	Cibus	133.56 Mn	113.13 Mn	-	-1,300.30%

Download Data